SAMD4A

Across TCGA pan-cancer cohorts, SAMD4A mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated SAMD4A data layer compared with 23 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher SAMD4A mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated SAMD4A expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

PDAC, LUAD, and CCRCC are the cancer types where SAMD4A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	II,III,IV	0.919	0.777	.003	12	view →
LUAD	OS	Median	III,IV	0.410	0.808	.025	4	view →
CCRCC	DFS	Median	IV	0.382	0.932	.031	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

SAMD4A–PDAC (OS)

Open the PDAC breakdown →